Menu
Recruiting NCT00768820

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

Phase IV Interventional Velocardiofacial Syndrome Williams Syndrome Fragile X Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: methylphenidate, fluoxetin, risperidone.
Who it may be relevant to
Registry conditions: Velocardiofacial Syndrome, Williams Syndrome, Fragile X Syndrome. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Overview

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Interventions

  • Drug methylphenidate, fluoxetin, risperidone
    first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Primary outcome measures

  • Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • chromosomal deletion proven by FISH examination

Exclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

Israel · 1 center
  • Schneider Children's Mediac Center of Israel — Petah Tikva

Identifiers

NCT: NCT00768820 · SCMCI082455CTIL

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗